Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals (AVIR)
NASDAQ:AVIR
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.41Last Year’s EPS
-0.75Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: -0.33%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook for Atea Pharmaceuticals, driven by successful phase two trial results for the HCV program and a strong financial position. While there were challenges related to workforce reduction and cirrhotic patient recruitment, the company's strategic initiatives and financial health suggest a promising future.Company Guidance
During Atea Pharmaceuticals' fourth quarter 2024 financial results call, guidance was provided on the company's strategic and financial trajectory. The company highlighted its significant progress in advancing the HCV program with a promising regimen, achieving a 98% cure rate in a phase two trial. The phase three program, set to begin enrollment in April 2025, is considered de-risked with a high likelihood of success, bolstered by robust phase two results and favorable multiscale modeling data. Financially, the company reported a strong position, with $454.7 million in cash and equivalents as of December 31, 2024, anticipated to extend their runway into 2028. Additionally, Atea announced a workforce reduction of approximately 20-25% to optimize expenditure, estimated to save around $15 million through 2027. The company has engaged Evercore to explore strategic partnerships, aiming to enhance shareholder value and capitalize on a multibillion-dollar market opportunity.Successful Phase 2 HCV Trial Results
The global phase two trial for the HCV program demonstrated a 98% cure rate with a short eight-week treatment, indicating strong potential for best-in-class hepatitis C treatment.
Initiation of Phase 3 HCV Program
Following positive phase two results and a successful FDA meeting, the company is initiating a global phase three program for its HCV regimen.
Strong Financial Position
Atea Pharmaceuticals reported $454.7 million in cash, cash equivalents, and marketable securities, providing a cash runway extending into 2028.
Cost-Reduction Measures
The company announced a workforce reduction of 20-25%, expected to save approximately $15 million through 2027.
---
AVIR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AVIR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | $3.00 | $2.99 | -0.33% |
| Nov 07, 2024 | $3.44 | $3.50 | +1.74% |
| Aug 07, 2024 | $3.27 | $3.50 | +7.03% |
| May 14, 2024 | $3.96 | $3.71 | -6.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Atea Pharmaceuticals (AVIR) report earnings?
Atea Pharmaceuticals (AVIR) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Atea Pharmaceuticals (AVIR) earnings time?
Atea Pharmaceuticals (AVIR) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AVIR EPS forecast?
AVIR EPS forecast for the fiscal quarter 2025 (Q1) is -0.41.
---